Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...